Notice · For research and educational reference. Not medical advice. Intended for licensed professionals. Nothing on this site is offered for sale other than informational access.

All Info Peptides
All monographs

Cognitive & Neurotrophic

Melanotan-1

Also known as · MT-1 · Afamelanotide

Overview

A linear α-MSH analogue with MC1R-selective agonism. Approved in the EU and US as afamelanotide (sustained-release implant) for erythropoietic protoporphyria.

Research profile · for clinicians

Based on research: an α-MSH analogue with MC1R selectivity, approved as afamelanotide for erythropoietic protoporphyria. Mechanistically studied for melanin upregulation and photoprotection in light-sensitive dermatologic disorders.

Mechanism of action

MC1R agonism on melanocytes upregulates eumelanin synthesis, providing photoprotective effects in light-sensitive disorders.

Research record

  • [01]CUV029 and CUV039 Phase III trials in erythropoietic protoporphyria.
  • [02]Investigated in vitiligo and Hailey-Hailey disease research.

Selected references

  • Afamelanotide for erythropoietic protoporphyria

    NEJM, 2015